This online seminar provides an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers in order to significantly impact patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer, where between 30 percent and 40 percent of cases recur. However, the only currently available monitoring blood test misses 74 percent of resectable recurrences.

In this webinar, Dr. Lawrence LaPointe, CEO of Clinical Genomics, discusses how his team is working with Qiagen to develop a ctDNA test for colorectal cancer recurrence monitoring.

Additionally, Dr. Martin Horlitz briefly shares how Qiagen's ctDNA extraction chemistries are compliant with ISO and IVD quality guidelines.